Abstract
Long-term nephrotoxicity of ifosfamide is occasionally progressive, and, in such case, there has been no specific treatment to prevent progression. It has been reported that the presence of karyomegalic interstitial nephritis, which is rare type of interstitial nephritis, may be related to ifosfamide-induced nephropathy with poor prognosis and resistant to the immunosuppressive therapy. A 15-year-old boy presented with progressive nephrotoxicity 3 years after systemic chemotherapy with ifosfamide and cisplatin for the treatment of osteosarcoma. Renal biopsy revealed the severe tubulointerstitial nephritis with tubular atrophy and focal global and segmental glomerular sclerosis. It also showed tubular epithelial cells with variably sized nuclei, some of which were massively enlarged, abnormal hyperchromatic, irregular shaped, and bizarre-appearing. These morphological changes were suggestive of the histology of karyomegalic interstitial nephritis. Corticosteroid retarded the progression of nephrotoxicity. The present case is the first report, suggesting that corticosteroid was effective against the late-onset renal toxicity by ifosfamide therapy. Our case also suggests that karyomegalic interstitial nephritis may be the result of long-term nephrotoxicity of ifosfamide. Since concurrent treatment with cisplatin is one of the risk factors for ifosfamide nephrotoxicity, there is a possibility that cisplatin may have a synergetic effect with ifosfamide for producing karyomegalic interstitial nephritis.
This is a preview of subscription content, log in via an institution to check access.
References
Hanly L, Chen N, Rieder M, Koren G. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin Drug Saf. 2009;8:155–68.
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer. 2010;54:983–9.
Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC, Kinsey SE. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol. 1996;27:149–55.
Jones DP, Spunt SL, Green D, Springate JE. Renal late effects in patients treated for cancer in childhood: a report from the children’s oncology group. Pediatr Blood Cancer. 2008;51:724–31.
Rossi R, Pleyer J, Schäfers P, Kuhn N, Kleta R, Deufel T, Jürgens H. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol. 1999;32:177–82.
Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. United Kingdom Children’s Cancer Study Group. Br J Cancer. 2000;82:1636–45.
Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994;12:159–65.
Morland BJ, Mann JR, Milford DV, Raafat F, Stevens MC. Ifosfamide nephrotoxicity in children: histopathological features in two cases. Med Pediatr Oncol. 1996;27:57–61.
McCulloch T, Prayle A, Lunn A, Watson AR. Karyomegalic-like nephropathy, Ewing’s sarcoma and ifosfamide therapy. Pediatr Nephrol. 2011;26:1163–6.
Friedlaender MM, Haviv YS, Rosenmann E, Peylan-Ramu N. End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy. Am J Nephrol. 1998;18:131–3.
Berns JS, Haghighat A, Staddon A, Cohen RM, Schmidt R, Fisher S, Rudnick MR, Tomaszewski JE. Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients. Cancer. 1995;76:497–500.
Willemse PH, de Jong PE, Elema JD, Mulder NH. Severe renal failure following high-dose ifosfamide and mesna. Cancer Chemother Pharmacol. 1989;23:329–30.
Monga G, Banfi G, Salvadore M, Amatruda O, Bozzola C, Mazzucco G. Karyomegalic interstitial nephritis: report of 3 new cases and review of the literature. Clin Nephrol. 2006;65:349–55.
Bhandari S, Kalowski S, Collett P, Cooke BE, Kerr P, Newland R, Dowling J, Horvath J. Karyomegalic nephropathy: an uncommon cause of progressive renal failure. Nephrol Dial Transplant. 2002;17:1914–20.
Ateşşahín A, Ceríbaşi AO, Yuce A, Bulmus O, Cikim G. Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol. 2007;100:121–6.
Spoendlin M, Moch H, Brunner F, Brunner W, Burger HR, Kiss D, Wegmann W, Dalquen P, Oberholzer M, Thiel G, Mihatsch MJ. Karyomegalic interstitial nephritis: further support for a distinct entity and evidence for a genetic defect. Am J Kidney Dis. 1995;25:242–52.
Sehirli O, Sakarcan A, Velioğlu-Oğünç A, Cetinel S, Gedik N, Yeğen BC, Sener G. Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol. 2007;222:33–41.
Informed consent
Informed consent was obtained from the mother of this patient for publication of this case report and any accompanying images, because this patient was under 16 years of age.
Conflict of interest
The authors have declared that no conflict of interest exists.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Matsuura, T., Wakino, S., Yoshifuji, A. et al. Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid. CEN Case Rep 3, 226–231 (2014). https://doi.org/10.1007/s13730-014-0124-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-014-0124-3